Treatment practices of mild cognitive impairment in California Alzheimer's disease centers

Journal of the American Geriatrics Society

Volumn 57, Issue 4, 2009, Pages 686-690

  Weinstein, Andrea M ^b,c   Barton, Cynthia ^a,b,d   Ross, Leslie ^a,d   Kramer, Joel H ^a,d   Yaffe, Kristine ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Alzheimer's disease; Cholinesterase inhibitors; Medications; Mild cognitive impairment

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; CERIVASTATIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUINDOSTATIN; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; MEVINOLIN; PRAVASTATIN; RIVASTIGMINE; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

AGED; AGING; AMNESIA; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; OFF LABEL DRUG USE; RACE DIFFERENCE; SEX RATIO; UNITED STATES;

AGED; ALZHEIMER DISEASE; ANTIOXIDANTS; CALIFORNIA; CHI-SQUARE DISTRIBUTION; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; DOPAMINE AGENTS; FEMALE; FOLIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MEMANTINE; NOOTROPIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 63849224187     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2009.02200.x     Document Type: Article

References (30)

1. Lopez OL, Jagust WJ, DeKosky ST et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 2003 60 : 1385 1389.
2. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999 56 : 303 308.
3. Yaffe K, Petersen RC, Lindquist K et al. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 2006 22 : 312 319.
4. Rabins PV, Blacker D, Rovner BW et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 2007 164 : 5 56.
5. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997 336 : 1216 1222.
6. Wolozin B, Kellman W, Ruosseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000 57 : 1439 1443.
7. Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005 62 : 753 757.
8. Masse I, Bordet R, Deplanque D et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005 76 : 1624 1629.
9. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 2001 CD003160
10. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002 360 : 1623 1630.
11. Morris MS, Jacques PF, Rosenberg IH et al. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001 73 : 927 933.
12. California Department of Public Health Services. Alzheimer's Research Centers of California, Minimum Uniform Dataset. San Francisco : California Department of Health Services, 1999.
13. Chui HC, Victoroff JI, Margolin D et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992 42 : 473 480.
14. Chui HC, Mack W, Jackson JE et al. Clinical criteria for the diagnosis of vascular dementia: A multicenter study of comparability and interrater reliability. Arch Neurol 2000 57 : 191 196.
15. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. 1994 : Washington, DC : American Psychiatric Association.
16. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005 352 : 2379 2388.
17. Blessed G, Tomlinson BE, Roth M. Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull 1988 24 : 705 708.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
19. Cerner Multum, Inc. Lexicon [on-line]. Available at Accessed August 2008.
20. Tinklenberg JR, Kraemer HC, Yaffe K et al. Donepezil treatment and Alzheimer disease: Can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? Am J Geriatr Psychiatry 2007 15 : 953 960.
21. Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study. Lancet Neurol 2007 6 : 501 512.
22. Winblad B, Gauthier S, Scinto L et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008 70 : 2024 2035.
23. Winblad B, Jelic V. Treating the full spectrum of dementia with memantine. Int J Geriatr Psychiatry 2003 18 : S41 S46.
24. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005 293 : 1338 1347.
25. Yaffe K, Clemons TE, McBee WL et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: A randomized, controlled trial. Neurology 2004 63 : 1705 1707.
26. Sparks DL, Sabbagh M, Connor D et al. Statin therapy in Alzheimer's disease. Acta neurologica Scandinavica 2006 185 : 78 86.
27. de Lau LM, Refsum H, Smith AD et al. Plasma folate concentration and cognitive performance: Rotterdam Scan Study. Am J Clin Nutr 2007 86 : 728 734.
28. Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008 300 : 1774 1783.
29. Stott DJ, MacIntosh G, Lowe GD et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 2005 82 : 1320 1326.
30. Mooijaart SP, Gussekloo J, Frolich M et al. Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: The Leiden 85-Plus study. Am J Clin Nutr 2005 82 : 866 871.